Company Filing History:
Years Active: 1995-1997
Title: The Innovations of David N. Brems
Introduction
David N. Brems, an accomplished inventor located in Indianapolis, IN, has made significant contributions to the field of biotechnology. With a total of 3 patents to his name, his work primarily focuses on developing innovative analogs of somatotropins and insulin, addressing critical needs in the management of various health conditions.
Latest Patents
Among his notable inventions are the **Somatotropin analogs**, which involve modifications to animal somatotropins, specifically targeting amino acids between residues 96 to 133. These changes aim to reduce hydrophobicity or enhance helical stability, making these analogs potentially more effective in therapeutic applications. Additionally, he has developed **AspB1 insulin analogs**, which introduce an aspartic acid modification at position 1 of the B chain. This innovation, combined with an optional glutamine modification at position 13, results in altered physico-chemical and pharmacokinetic properties that allow for longer-acting insulin. These modifications are especially beneficial in treating hyperglycemia due to their solubility and increased self-associative tendencies.
Career Highlights
David's career highlights include tenures at renowned companies such as Eli Lilly and Company and The Upjohn Company, where he has been able to leverage his expertise in pharmaceuticals and biotechnology. His work has significantly contributed to advancements in diabetic therapies and hormone treatments, making him a valued figure in the innovation landscape.
Collaborations
Throughout his career, David has collaborated with various professionals in his field. Notable coworkers include Diane L. Bakaysa and Bruce H. Frank, both of whom have likely contributed to the development and execution of innovative projects that highlight David's inventive prowess.
Conclusion
David N. Brems stands out as a prominent inventor with a focus on biopharmaceutical innovation. His patents reflect a commitment to improving therapeutic options in healthcare, particularly in the management of diabetes and other metabolic disorders. As he continues to innovate, his contributions will undoubtedly leave a lasting impact in the biotechnological domain.